Literature DB >> 33385239

Relationship between the dynamic changes of serum 2019-nCoV IgM/IgG and patient immunity after 6 month hospital discharge.

Yinfeng Shen1, Yuanming Ba2, Yaling Hu3, Linqun Wang3, Weinan Li3.   

Abstract

OBJECTIVES: To investigate the relationship between the dynamic changes of serum 2019-nCoV IgM/IgG and immunity alteration for patients after 6-month hospital discharge.
METHODS: One IgM(+) and IgG(-), 32 IgM(+) and IgG(+), 38 IgM(-) and IgG(+), and 40 IgM(-) and IgG(-) patients were included. Demographic data were collected. IgM and IgG antibodies, hypersensitive C-reactive protein (hs-CRP), interleukin-6 (IL-6) and lymphocyte subsets in serum were determined at weeks 0, 2 and 4.
RESULTS: The hs-CRP and IL-6 levels of all patients were within the normal ranges. The number of patients with all lymphocyte subset testing items within normal ranges was 12/110 (10.9%) at week 0, 15/110 (13.6%) at week 2 and 18/110 (16.4%) at week 4. The percentages of CD8 + cells, NK cells and B lymphocytes in the IgM(+) and IgG(+) group were quite different from those in the IgM(-) and IgG(+) group and the IgM(-) and IgG(-) group, with much higher percentages of CD8 + cells and much lower percentages of NK cells and B lymphocytes at weeks 0, 2 and 4. Twelve IgM(+) patients in the IgM(+) and IgG(+) group converted to IgM(-), and the percentages of NK cells and B lymphocytes in these patients were significantly increased at week 4.
CONCLUSIONS: The changes of serum IgM and IgG are closely related to immunity in patients in the recovery stage. However, immunity does not recover when the patients test negative for these antibodies.

Entities:  

Keywords:  Antibodies; COVID-19; Immunity; Recovery stage

Year:  2021        PMID: 33385239     DOI: 10.1007/s00011-020-01429-8

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  5 in total

Review 1.  Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19).

Authors:  Balamurugan Shanmugaraj; Konlavat Siriwattananon; Kittikhun Wangkanont; Waranyoo Phoolcharoen
Journal:  Asian Pac J Allergy Immunol       Date:  2020-03       Impact factor: 2.310

2.  East-West differences in clinical manifestations of COVID-19 patients: A systematic literature review and meta-analysis.

Authors:  Xiucheng Liu; Xiang Li; Teng Sun; Hao Qin; Yeqing Zhou; Chenghang Zou; Junli Cao; Hao Zhang
Journal:  J Med Virol       Date:  2021-02-23       Impact factor: 2.327

3.  Characteristics of inflammatory factors and lymphocyte subsets in patients with severe COVID-19.

Authors:  Ming Ni; Fang-Bing Tian; Dan-Dan Xiang; Bing Yu
Journal:  J Med Virol       Date:  2020-06-09       Impact factor: 2.327

Review 4.  The Role of Antibody Testing for SARS-CoV-2: Is There One?

Authors:  Elitza S Theel; Patricia Slev; Sarah Wheeler; Marc Roger Couturier; Susan J Wong; Kamran Kadkhoda
Journal:  J Clin Microbiol       Date:  2020-07-23       Impact factor: 5.948

5.  Structural Basis for Designing Multiepitope Vaccines Against COVID-19 Infection: In Silico Vaccine Design and Validation.

Authors:  Sonia Verma; Sukrit Srivastava; Mohit Kamthania; Rupinder Kaur; Ruchi Kiran Badyal; Ajay Kumar Saxena; Ho-Joon Shin; Michael Kolbe; Kailash C Pandey
Journal:  JMIR Bioinform Biotech       Date:  2020-06-19
  5 in total
  2 in total

1.  Measurement of antibody levels in patients with COVID-19 over time by immunofluorescence assay: a longitudinal observational study.

Authors:  Betul Borku Uysal; Serap Yavuzer; Mehmet Sami Islamoglu; Mahir Cengiz
Journal:  J Int Med Res       Date:  2022-01       Impact factor: 1.671

2.  Epidemiological study using IgM and IgG antibody titers against SARS-CoV-2 in The University of Tokyo, Japan (UT-CATS).

Authors:  Akihisa Mitani; Kensuke Hamada; Naoyuki Yoshikawa; Yoshifumi Morita; Takeshi Horie; Yukiko Inoue; Minako Saito; Takashi Ishii; Mitsuhiro Sunohara; Ryota Takahashi; Noriko Emoto; Nahoko Nishimoto; Yoko Murano; Sachiko Okazaki; Shoko Tateishi; Atsushi Yao; Takuya Shimura; Makoto Kurano; Yutaka Yatomi; Shintaro Yanagimoto
Journal:  J Infect Chemother       Date:  2021-06-12       Impact factor: 2.211

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.